August 28, 2019
- Drug Firm Annual Registration Status (updated)
- Drug Firm Annual Registration Status Download File (updated)
- Drug Safety Communication (DSC) in Spanish: La FDA aprueba un Recuadro de advertencia acerca del aumento en el riesgo de coágulos de sangre y muerte con dosis más altas del medicamento tofacitinib para la artritis y colitis ulcerosa (Xeljanz, Xeljanz XR)
- Placebos and Blinding in Randomized Controlled Cancer Clinical Trials for Drug and Biological Products Guidance for Industry
- National Drug Code Directory (updated)
- Wholesale Distributor and Third-Party Logistics Providers Reporting (updated)
No hay comentarios:
Publicar un comentario